Head-To-Head Review: Invivyd (IVVD) versus Its Competitors

Invivyd (NASDAQ:IVVD – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Invivyd to related companies based on the strength of its dividends, analyst recommendations, valuation, risk, profitability, earnings and institutional ownership.

Earnings and Valuation

This table compares Invivyd and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Invivyd $53.43 million -$52.49 million -1.63
Invivyd Competitors $715.39 million $10.31 million -18.32

Invivyd’s competitors have higher revenue and earnings than Invivyd. Invivyd is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Invivyd has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Invivyd’s competitors have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Profitability

This table compares Invivyd and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invivyd -183.90% -59.73% -48.97%
Invivyd Competitors -12,319.70% -407.93% -30.95%

Institutional and Insider Ownership

70.4% of Invivyd shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 12.2% of Invivyd shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Invivyd and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invivyd 1 1 3 0 2.40
Invivyd Competitors 9931 15320 45696 1605 2.54

Invivyd presently has a consensus target price of $10.00, suggesting a potential upside of 1,759.77%. As a group, “Biotechnology” companies have a potential upside of 131.74%. Given Invivyd’s higher probable upside, equities research analysts plainly believe Invivyd is more favorable than its competitors.

Summary

Invivyd competitors beat Invivyd on 7 of the 12 factors compared.

About Invivyd

(Get Free Report)

Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.

Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.